Company intelligence / Profile preview

Trisol Medical

Yokneam Ilit, North District, Israeltrisol-medical.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Trisol Medical is developing a transcatheter tricuspid valve replacement device designed to eliminate tricuspid regurgitation while preserving right ventricular function. The company has initiated early feasibility studies in the United States and has reported first implantations as of August 2023. The device features a nitinol frame with dome-shaped leaflets and is intended for fully percutaneous implantation in patients with severe tricuspid regurgitation.

Therapeutic areas: Cardiovascular
Modalities: DeviceTranscatheter heart valve replacement device
Industry: Implantable Medical Devices

Partnerships

European Union Horizon 2020 research and innovation programme funding support (EIC Fund/EIC Accelerator grant)

Beyond the preview

Go deeper on Trisol Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trisol Medical.

Explore the full profile